000538.SZ
云南白药
SZSE · Healthcare · C 制造业 · CN
CNY 49.50
+0.34%Year over year
Reported trailing growth
- Revenue
- +4.6%
- EBITDA
- —
- EBIT
- +1.6%
- EPS
- +5.7%
- Free cash flow
- +11.8%
- Operating cash flow
- +5.2%
Forward estimates
Based on analyst estimates
- Revenue
- -0.6%
- EBITDA
- +18.9%
- EPS
- +13.7%
Three-year CAGR
- Revenue
- +4.1%
- EBITDA
- +19.2%
- EBIT
- +21.4%
- Net income
- +19.7%
- EPS
- +15.0%
- Free cash flow
- +14.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026